A community hospital oncologist speaks about their current usage of MRD and monitoring technologies. Though they currently use these technologies in the NSCLC setting along with complementary technologies like imaging, they have very optimistic perspectives of the use of these technologies for breast cancer, CRC, prostate, and renal cancers in the future. While reimbursement and coverage may be considered a pain point in the adoption of more advanced testing, this stakeholder notes that payers are fairly cooperative with covering tests that occur <2x a year from their current vendors. This oncologist is familiar with multiple vendors but primarily uses Caris, and they expect the MRD and monitoring landscape to have opportunities for multiple players to succeed. They have already started exploring post adjuvant concordance with post-adjuvant PET scans as a form of internal validation.

Campaign Details

MRD Ad Board

DeciBio conducted ~11 interviews with medical oncologists and biopharma executives to understand how minimal residual disease (MRD) testing and ctDNA monitoring are currently integrated into solid tumor care